MJP2 Cannabis PTSD Trial Begins Enrolling 320 Veterans: Inside the FDA-Approved Study

The largest, most rigorous clinical trial of whole-plant cannabis for veterans with post-traumatic stress disorder is officially underway. The study, known as MJP2, has begun enrolling participants in Michigan and two additional states in the first quarter of 2026, according to updates from the Multidisciplinary Association for Psychedelic Studies (MAPS) and the Scottsdale Research Institute. Funded by a $12.9 million grant from the Michigan Veteran Marijuana Research Grant Program and cleared by the FDA after years of regulatory wrangling, MJP2 will enroll 320 U.S. veterans with moderate to severe PTSD.

For a field that has had to rely for decades on observational studies, self-report surveys, and a single 76-participant pilot, MJP2 is the statistical event the cannabis-for-PTSD conversation has been waiting for.

Why This Study Is Different

Most public claims about cannabis helping with PTSD — including the frequently cited "40 to 60 percent reduction in symptoms" figure that circulates in veteran advocacy circles — come from observational research, retrospective chart reviews, or small placebo-lacking pilots. Those studies can generate hypotheses, but they cannot separate cannabis's effect from expectancy, self-selection, or the natural course of PTSD symptoms.

MJP2 is a randomized, placebo-controlled, double-blind trial. Veterans will be randomized to one of four arms:

1. High THC / low CBD cannabis flower
2. High CBD / low THC cannabis flower
3. Balanced High THC / High CBD flower
4. Placebo flower

The placebo arm is the quiet breakthrough. For years, the FDA's central objection to cannabis PTSD research was the difficulty of producing a convincing placebo cannabis product. Researchers have since validated a placebo strain that is visually, texturally, and aromatically similar to active cannabis but contains minimal cannabinoids — a concession that took nearly a decade to clear.

The Investigators and Sites

The MJP2 trial is being coordinated by Marcel Bonn-Miller, PhD of the University of Pennsylvania, a veteran researcher whose 2021 pilot study was the last federally authorized PTSD-cannabis trial in the United States.

Site principal investigators include:

• Sue Sisley, MD at the Scottsdale Research Institute in Phoenix — the physician who spent nearly a decade fighting for the original FDA approval to study whole-plant cannabis.
• Ryan Vandrey, PhD at Johns Hopkins University in Baltimore — a behavioral pharmacologist whose work on cannabis dose-response has shaped NIDA research design.
• A third site in Michigan, which will be announced formally when enrollment opens.

The three-site design matters because PTSD trials are notoriously sensitive to local therapist effects and community differences. Spreading enrollment across Arizona, Maryland, and Michigan is an attempt to demonstrate that any observed benefit is not an artifact of one clinic's culture or one investigator's patient panel.

What the Study Is Measuring

The primary endpoint is change on the Clinician-Administered PTSD Scale for DSM-5, or CAPS-5 — the gold standard for clinical PTSD trials and the instrument used in the MDMA-for-PTSD studies that reached Phase III at the FDA in 2023. Secondary endpoints include sleep quality, quality of life, anxiety and depression measures, and safety and tolerability outcomes.

Importantly, MJP2 uses real-world smoked cannabis flower, self-titrated by participants within a pre-specified dose ceiling. Unlike pharmaceutical cannabinoid trials — where researchers give precise oral doses of isolated THC or CBD — MJP2 is designed to reflect how veterans actually use cannabis. That makes its results harder to translate into a prescription drug, but much more relevant to the policy conversation about medical cannabis access.

The Science So Far

Cannabis's plausible mechanism of action in PTSD is neither new nor exotic. The endocannabinoid system is densely expressed in the amygdala, hippocampus, and prefrontal cortex — the same structures implicated in fear extinction, threat response, and intrusive memory processing. Preclinical rodent work has repeatedly shown that CB1 receptor activation can accelerate fear extinction, the process by which a previously traumatic cue stops triggering a fear response.

That is why the study is testing CBD-dominant and balanced formulations alongside high-THC cannabis. Animal and small human studies suggest CBD may blunt the acute anxiogenic effects of high-dose THC and independently support sleep quality — two outcomes that matter enormously in PTSD. A 2026 University of California review concluded that balanced THC:CBD formulations produced "the most effective and stable" pain and anxiety outcomes in chronic-pain populations, and the MJP2 design directly tests whether a similar pattern holds in PTSD.

What Veterans Are Actually Using

Against the backdrop of MJP2, the real-world cannabis behavior of U.S. veterans continues at scale. Roughly 9 percent of veterans using VA services report current cannabis use, with substantially higher rates among veterans with PTSD. A separate VA San Diego Healthcare System trial, funded by a $1.3 million VA grant and enrolling 136 veterans, is testing CBD as an add-on to prolonged exposure therapy — the gold-standard PTSD psychotherapy.

The overlap of these trials suggests the federal research ecosystem is moving, however slowly, from a debate over whether to study cannabis in veterans to a more granular debate about which formulation, which route of administration, and which combination with existing therapy.

What This Means

If MJP2 produces a positive readout — meaning one or more of the active cannabis arms produces a clinically meaningful reduction in CAPS-5 scores relative to placebo — it would be the first Phase II-style evidence to meet the FDA's methodological bar for cannabis PTSD treatment. That is the threshold needed to trigger serious regulatory conversations about whole-plant cannabis as an approved PTSD therapy, and to give VA physicians the scientific cover to prescribe or recommend cannabis for trauma-related symptoms.

If MJP2 produces a null result, the story is equally important. It would not mean cannabis does not help any veteran with PTSD — real-world populations are always more heterogeneous than trial populations — but it would force the field to stop quoting uncontrolled "40 to 60 percent" reduction figures as if they came from randomized data.

Either outcome is a step toward replacing advocacy math with clinical trial math. Results from the first cohort are expected in late 2027 or early 2028.

Key Takeaways

• MJP2 is enrolling 320 U.S. veterans with moderate to severe PTSD across Arizona, Maryland, and Michigan, funded by a $12.9M Michigan state grant.
• The trial is the first randomized, placebo-controlled, double-blind study of whole-plant cannabis for PTSD to begin enrollment in the U.S.
• Four arms test high-THC, high-CBD, balanced THC/CBD, and placebo flower; primary endpoint is CAPS-5 score change.
• A separate VA San Diego CBD-plus-prolonged-exposure trial is enrolling 136 veterans, adding a psychotherapy-combination angle.
• Topline results from MJP2 are expected in late 2027 or early 2028.

Explore cannabis news, find dispensaries, and join the community at Budpedia.